Swedish Orphan Biovitrum AB (publ) (SWOBY)

Market Cap	10.60B
Revenue (ttm)	2.84B
Net Income (ttm)	459.76M
Shares Out	n/a
EPS (ttm)	1.33
PE Ratio	23.06
Forward PE	19.03
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,284
Average Volume	1,324
Open	15.75
Previous Close	n/a
Day's Range	15.75 - 15.75
52-Week Range	12.75 - 17.20
Beta	0.26
RSI	48.66
Earnings Date	Oct 23, 2025

About SWOBY

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocy...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1939
• Employees: 1,806
• Stock Exchange: OTCMKTS
• Ticker Symbol: SWOBY

Financial Performance

In 2024, SWOBY's revenue was 26.03 billion, an increase of 17.65% compared to the previous year's 22.12 billion. Earnings were 3.89 billion, an increase of 61.27%.

Financial numbers in SEK